U-Chart Analysis:WAKAMOTO PHARMACEUTICAL CO.,LTD.:4512

※The values of financial statements might be different from the actual ones. Please confirm the original. [instructions]

Main FunctionHelp Company NameHelp CodeHelp Types of IndustryHelp Market Name Fiscal Year End Year of Listing
Browse U-Chart Add to 'Companies Comparison' list Compare Lustrum Ullet index WAKAMOTO PHARMACEUTICAL CO.,LTD. Go to web site 4512 Medicals 東証スタンダード March 1, 2000 1949.
Analysis u.gifU-Chart AnalysisHelp hikaku.gifAdd to 'Companies Comparison' listHelp u2.gifCompare LustrumHelp mark.gifUllet indexHelp
Accounts Information Balance Sheet Profit and Loss Account Cash Flow Statement
Display

WAKAMOTO PHARMACEUTICAL CO.,LTD. Balance Sheet(B/S)

[Show - Hide] U-Chart:Balance Sheet (B/S)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

WAKAMOTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2024年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2023年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2022年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2021年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2020年3月期

[Show - Hide] Balance Sheet (B/S)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2024 March 31, 2023 March 31, 2022 March 31, 2021 March 31, 2020
Cash and Cash Equivalents 3,665 3,879 3,232 2,844 2,884
Other Current AssetsHelp 5,305 5,474 5,376 4,794 5,764
Tangible Fixed AssetsHelp 3,028 3,032 3,297 3,527 3,648
Intangible Fixed AssetHelp 357 202 196 201 485
Investments and OthersHelp 3,066 3,124 2,852 3,207 3,202
Total AssetsHelp 15,421 15,712 14,953 14,572 15,983
Total Current LiabilitiesHelp 3,395 3,804 3,471 3,184 4,033
Total Long-term LiabilitiesHelp 0 1 2 3 4
Shareholder's EquityHelp 12,026 11,907 11,481 11,386 11,947
Total LiabilitiesHelp 15,421 15,712 14,953 14,572 15,983

WAKAMOTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account(P/L)

[表示非表示] U-Chart:Profit and Loss Account (P/L)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

WAKAMOTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2024年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2023年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2022年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2021年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2020年3月期

[Show - Hide] Profit and Loss Account (P/L)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2024 March 31, 2023 March 31, 2022 March 31, 2021 March 31, 2020
Amount of Sales 7,738 8,660 8,383 8,896 10,917
Total Sales 7,738 8,660 8,383 8,896 10,917
Cost of SalesHelp 4,139 4,552 4,027 4,407 4,724
Other Costs and RevenueHelp 3,491 3,970 4,117 5,091 7,849
Total CostsHelp 7,629 8,522 8,145 9,498 12,573
Net RevenueHelp 3,600 4,108 4,356 4,489 6,193
Earnings Before TaxHelp 159 212 285 -703 -911
Net IncomeHelp 109 138 239 -602 -1,657
Net Income 109 138 239 -602 -1,657

WAKAMOTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement(C/F)

[表示非表示] U-Chart:Cash Flow Statement (C/F)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

WAKAMOTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2024年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2023年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2022年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2021年3月期 WAKAMOTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2020年3月期

[Show - Hide] Cash Flow Statement (C/F)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2024 March 31, 2023 March 31, 2022 March 31, 2021 March 31, 2020
Operating Cash Flow(OFC)Help -107 632 339 163 -155
Investing Cash Flow(ICF)Help -2 17 51 -200 -179
Financing Cash FlowHelp -105 -2 -2 -4 -44
Exchange Difference of Cash and Cash EquivalentsHelp 0 0 -0 0 -0
Net Increase and Decrease in Cash and Cash Equivalentsn -215 647 388 -40 -378

他社比較Help

Companies in 'Companies Comparison' list

Browsing historyHelp

Your reecently viewed companies

WAKAMOTO PHARMACEUTICAL CO.,LTD.

Company where related level is highHelp

STELLA PHARMA CORPORATION
NANO MRNA Co., Ltd.
CanBas Co.,Ltd.
Renascience Inc.
GNI Group Ltd.
CellSource Co., Ltd.
D.Western Therapeutics Institute, Inc.
Mochida Pharmaceutical Co.,Ltd.
Noile-Immune Biotech Inc.
Mitsubishi Tanabe Pharma Corporation